GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

13 Jun 2024
pmlive.com
License out/inFast TrackOligonucleotideClinical Study
GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers
Preview
Source: PMLiVE
GSK has entered into a multi-year data licence agreement with Ochre Bio to investigate the drivers of liver disease and accelerate the development of therapeutics, with the deal worth up to $37.5m.
The partnership gives GSK access to Ochre’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver data sets, as well as non-exclusive access to its library of historical liver data.
The companies have not specified what indications they will target, but both will use the data to build artificial intelligence (AI) models that allow for more precise experiments to aid in target choice.
Kim Branson, senior vice president, global head of AI and machine learning at GSK, said: “Ochre Bio’s platform will provide GSK with foundational data sets to create AI models, allowing us to better understand liver function and disease for the development of novel medicines.”
The agreement has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences.
Jack O’Meara, Ochre’s co-founder and chief executive officer, said: “Data innovation is as important as algorithmic innovation when investing in machine learning workflows… These large-scale, causal human data sets will be foundational for our respective liver research and development pipelines.”
GSK’s investigational antisense oligonucleotide bepirovirsen was granted fast track designation from the US Food and Drug Administration in February as a treatment for chronic hepatitis B, which affects nearly 300 million people worldwide.
“In addition to our programmes in MASH to hepatitis B, we are committed to addressing unmet needs in liver disease by generating unique data in human derived systems,” Branson said in the latest announcement.
The deal comes just one week after GSK said that it had acquired US-based Elsie Biotechnologies and its oligonucleotide discovery platform for $50m.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.